Vaginal and uterine drug delivery

Published on February 27, 2020   50 min

Other Talks in the Series: Drug Delivery

Hello, everyone. My name is José Luis Arias, from the University of Granada, Spain. It is my pleasure to start the talk on vaginal and uterine drug delivery, where we will analyze the need for drug delivery systems to these groups. The materials used for developing those drug delivery systems and some relevant specifics or peculiarities on the subject. Before starting the talk, let me thank you for the opportunity given to share my views on vaginal drug delivery systems.
Nanocarriers are drug microns in the submicron size that have been under extremely extensive research in an attempt to fundamentally change the conventional strategies for drug administration. Present advances in pharmaceutical nanotechnology have allowed the creation of versatile nanosystems such as nanoparticles, vesicles, and nanomedicines. That can be engineered to overcome barriers imposed by the organisms and delivery date therapeutic cargo in a temporally and in spatially controlled manner. Enable deep penetration into the body tissues, efficient internalization at the cellular level, and controlled drug release. Any pharmacologically active substance, regardless of its molecular weight, hydrophilic character and stability, or any other physicochemical properties including small molecule drugs, peptides, proteins, and DNA and RNA, can be very easily loaded into an adequate nanoparticle for introduction by almost any route of drug administration, to achieve efficient delivery to the site of index. Hence superior chemical and biological stability, ability to shield the loaded drug from degradation sources. A smartly tuned drug pharmacokinetics and biodistribution are a few examples to name among the unique features offered by these drug delivery platforms.